Abstract
Multiple myeloma (MM), a malignant plasma cell infiltration of the bone marrow, is generally considered incurable: resistance to multiple therapeutic drugs inevitably arises from tumor cell-intrinsic and tumor microenvironment (TME)-mediated mechanisms. Here we report that the proteoglycan tandem repeat 1 (PTR1) domain of the TME matrix protein, hyaluronan and proteoglycan link protein 1 (HAPLN1), induces a host of cell survival genes in MM cells and variable resistance to different classes of clinical drugs, including certain proteasome inhibitors, steroids, immunomodulatory drugs, and DNA damaging agents, in several MM cell lines tested. Collectively, our study identifies HAPLN1 as an extracellular matrix factor that can simultaneously confer MM cell resistance to multiple therapeutic drugs.
Funder
NIH
University of Wisconsin-Madison
University of Wisconsin Carbone Cancer Center
Publisher
Public Library of Science (PLoS)
Reference72 articles.
1. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back;G Bianchi;CA: a cancer journal for clinicians,2014
2. Multiple myeloma;RA Kyle;Blood,2008
3. MYELOMA PROTEINS AND THE CLINICAL RESPONSE TO MELPHALAN THERAPY;DE De Bergsagel;Science,1965
4. Melphalan in multiple myeloma;B Hoogstraten;Blood,1967
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献